Case Studies
Two illustrative programs showing how LabOS + Apollo compose end-to-end. These are strategic scenarios, not disclosed client engagements.
Case 1 · Indian generic pharma — oncology repurposing
Client profile
Top-5 Indian generic pharma (Sun Pharma–scale). Patent cliff on a blockbuster small molecule in 2028. Needs an innovation pipeline, not another ANDA. Budget: $2–3M for a 12-month discovery sprint.
Target Discovery on oral cancer
OmicsOS Hypothesis Agent over Apollo oral cancer cohort surfaces 12 ranked targets with India-specific fusion signals absent from TCGA. Two dossiers delivered; wet-lab validation plan routed to Syngene via Execution Broker.
Hit-to-lead on top target
Virtual screen + focused HTS. Learning Agent compresses SAR cycles from 6 weeks to 10 days per round. Lead nominated with ADMET profile and India-tuned PK flags.
Preclinical + regulatory handoff
Apollo patient-derived organoid efficacy panel. ClinicalBridge IND-enabling package for CDSCO. Client exits with owned IP and option to extend to IVD CDx sprint.
Outcome: 12-month program, ~$2.5M spend, lead candidate + IND path vs 24+ months and $8–12M traditional CRO route.
Case 2 · MNC pharma APAC — stratified Phase 2 design
Client profile
Global pharma APAC R&D head (Novartis/AZ-scale). Phase 2 immunotherapy in NSCLC underperforming in undifferentiated India enrollment. Needs biomarker-guided stratification using India cohort genetics.
Atlas-powered stratification
License India Biomarker Atlas responder signature. Retrospective match against Apollo NSCLC treated cohort — 40% trial size reduction projected.
IVD analytical lock
Companion diagnostic assay developed in parallel (subset of full IVD sprint). CDSCO-first path; FDA Q-Sub scheduled for Month 9.
Clinical platform early access (Q3 2026)
Decentralized enrollment via Apollo network with real-time stratification. LabOS Execution Broker handles site logistics.
Outcome: Stratified Phase 2 design, CDx in flight, APAC regulatory credibility — bundled Atlas license + IVD sprint + future clinical platform subscription.
Discuss a program
These scenarios map to our offerings stack. Contact skannan@oncophenomics.com to scope a sprint for your indication.